HAINAN HAIYAO(000566)2025-01-27 12:05Financial Performance - The company expects a net loss attributable to shareholders of approximately 90 million yuan for 2024, compared to a loss of 10.65 million yuan in the same period last year[3]. - The operating revenue is projected to be between 100 million and 120 million yuan, down from 147.86 million yuan in the previous year[3]. - The company anticipates an asset impairment loss of about 700 million yuan due to long-term equity investments and goodwill[5]. - The preliminary financial data will be detailed in the 2024 annual report, urging investors to make cautious decisions[10]. Research and Development - The company plans to enhance R&D investment and accelerate the launch of new products, collaborating with top pharmaceutical research institutions[7]. Marketing and Strategy - The marketing strategy will focus on optimizing the organizational structure and enhancing cost competitiveness through targeted market strategies[8]. - The company aims to expand its international business, particularly in Southeast Asia, Africa, and Latin America, while pursuing EU GMP certification[8]. Cost Management - Production costs will be strictly controlled, with measures to improve production efficiency and reduce material consumption[9]. - The company is committed to refining its budget control and optimizing financing structures to lower costs[9].